Total Liabilities Summary of Vcanbio Cell & Gene Engineering Corp., Ltd

Vcanbio Cell & Gene Engineering Corp., Ltd's latest annual total liabilities in 2023 was 1.61 Billion CNY , down -1.12% from previous year.
Vcanbio Cell & Gene Engineering Corp., Ltd's latest quarterly total liabilities in 2024 Q2 was 1.59 Billion CNY , up 0.23% from previous quarter.
Vcanbio Cell & Gene Engineering Corp., Ltd reported annual total liabilities of 1.63 Billion CNY in 2022, up 8.69% from previous year.
Vcanbio Cell & Gene Engineering Corp., Ltd reported annual total liabilities of 1.5 Billion CNY in 2021, up 8.96% from previous year.
Vcanbio Cell & Gene Engineering Corp., Ltd reported quarterly total liabilities of 1.59 Billion CNY for 2024 Q1, down -1.4% from previous quarter.
Vcanbio Cell & Gene Engineering Corp., Ltd reported quarterly total liabilities of 1.59 Billion CNY for 2024 Q2, up 0.23% from previous quarter.

Annual Total Liabilities Chart of Vcanbio Cell & Gene Engineering Corp., Ltd (2023 - 1992)

Historical Annual Total Liabilities of Vcanbio Cell & Gene Engineering Corp., Ltd (2023 - 1992)

Year	Total Liabilities	Total Liabilities Growth
2023	1.61 Billion CNY	-1.12%
2022	1.63 Billion CNY	8.69%
2021	1.5 Billion CNY	8.96%
2020	1.37 Billion CNY	-3.55%
2019	1.42 Billion CNY	-2.14%
2018	1.45 Billion CNY	6.84%
2017	1.36 Billion CNY	9.08%
2016	1.25 Billion CNY	10.35%
2015	1.13 Billion CNY	-10.01%
2014	1.26 Billion CNY	52.82%
2013	824.89 Million CNY	-13.34%
2012	951.88 Million CNY	64.49%
2011	578.7 Million CNY	9.69%
2010	527.55 Million CNY	14.51%
2009	460.7 Million CNY	16.51%
2008	395.42 Million CNY	-1.94%
2007	403.22 Million CNY	1.99%
2006	395.34 Million CNY	22.46%
2005	322.84 Million CNY	29.68%
2004	248.95 Million CNY	-8.16%
2003	271.06 Million CNY	29.33%
2002	209.59 Million CNY	-42.94%
2001	367.3 Million CNY	50.29%
2000	244.4 Million CNY	-0.34%
1999	245.24 Million CNY	-4.46%
1998	256.69 Million CNY	-19.66%
1997	319.5 Million CNY	76.5%
1996	181.02 Million CNY	-3.57%
1995	187.72 Million CNY	70.8%
1994	109.9 Million CNY	145.09%
1993	44.84 Million CNY	24.05%
1992	36.15 Million CNY	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q3	1.6 Billion CNY	0.43%
2024 Q1	1.59 Billion CNY	-1.4%
2024 Q2	1.59 Billion CNY	0.23%
2023 Q2	1.6 Billion CNY	2.31%
2023 Q1	1.57 Billion CNY	-3.62%
2023 FY	1.61 Billion CNY	-1.12%
2023 Q4	1.61 Billion CNY	0.34%
2023 Q3	1.6 Billion CNY	-0.05%
2022 Q4	1.63 Billion CNY	2.16%
2022 Q3	1.59 Billion CNY	3.13%
2022 Q2	1.54 Billion CNY	-0.34%
2022 Q1	1.55 Billion CNY	3.5%
2022 FY	1.63 Billion CNY	8.69%
2021 Q4	1.5 Billion CNY	0.47%
2021 Q1	1.42 Billion CNY	3.45%
2021 Q2	1.44 Billion CNY	1.5%
2021 FY	1.5 Billion CNY	8.96%
2021 Q3	1.49 Billion CNY	3.28%
2020 Q2	1.4 Billion CNY	-0.22%
2020 Q1	1.4 Billion CNY	-1.54%
2020 Q3	1.4 Billion CNY	-0.18%
2020 Q4	1.37 Billion CNY	-1.65%
2020 FY	1.37 Billion CNY	-3.55%
2019 FY	1.42 Billion CNY	-2.14%
2019 Q2	1.48 Billion CNY	3.99%
2019 Q3	1.46 Billion CNY	-1.3%
2019 Q4	1.42 Billion CNY	-2.72%
2019 Q1	1.43 Billion CNY	-1.99%
2018 Q1	1.32 Billion CNY	-2.67%
2018 FY	1.45 Billion CNY	6.84%
2018 Q4	1.45 Billion CNY	1.88%
2018 Q3	1.43 Billion CNY	7.22%
2018 Q2	1.33 Billion CNY	0.49%
2017 Q2	1.36 Billion CNY	6.61%
2017 Q4	1.36 Billion CNY	-4.06%
2017 Q3	1.42 Billion CNY	4.65%
2017 FY	1.36 Billion CNY	9.08%
2017 Q1	1.27 Billion CNY	1.91%
2016 Q4	1.25 Billion CNY	0.49%
2016 Q3	1.24 Billion CNY	-0.52%
2016 FY	1.25 Billion CNY	10.35%
2016 Q1	1.07 Billion CNY	-5.31%
2016 Q2	1.25 Billion CNY	16.57%
2015 Q2	1.22 Billion CNY	16.31%
2015 FY	1.13 Billion CNY	-10.01%
2015 Q1	1.04 Billion CNY	-16.76%
2015 Q4	1.13 Billion CNY	9.34%
2015 Q3	1.03 Billion CNY	-14.99%
2014 Q2	860 Million CNY	4.13%
2014 Q1	825.9 Million CNY	0.12%
2014 Q4	1.26 Billion CNY	44.3%
2014 FY	1.26 Billion CNY	52.82%
2014 Q3	873.57 Million CNY	1.58%
2013 Q3	1.03 Billion CNY	3.67%
2013 Q4	824.89 Million CNY	-20.2%
2013 FY	824.89 Million CNY	-13.34%
2013 Q1	945.64 Million CNY	-0.66%
2013 Q2	997.12 Million CNY	5.44%
2012 Q3	923.82 Million CNY	-1.72%
2012 Q4	951.88 Million CNY	3.04%
2012 FY	951.88 Million CNY	64.49%
2012 Q1	900.18 Million CNY	55.55%
2012 Q2	940 Million CNY	4.42%
2011 FY	578.7 Million CNY	9.69%
2011 Q3	545.31 Million CNY	-2.93%
2011 Q4	578.7 Million CNY	6.12%
2011 Q2	561.79 Million CNY	2.93%
2011 Q1	545.78 Million CNY	3.46%
2010 Q3	522.41 Million CNY	6.0%
2010 Q4	527.55 Million CNY	0.99%
2010 FY	527.55 Million CNY	14.51%
2010 Q1	484.28 Million CNY	5.12%
2010 Q2	492.82 Million CNY	1.76%
2009 FY	460.7 Million CNY	16.51%
2009 Q1	414.62 Million CNY	4.86%
2009 Q3	403.51 Million CNY	-5.91%
2009 Q2	428.86 Million CNY	3.43%
2009 Q4	460.7 Million CNY	14.18%
2008 Q1	395.69 Million CNY	-1.87%
2008 FY	395.42 Million CNY	-1.94%
2008 Q2	413.98 Million CNY	4.62%
2008 Q3	383.82 Million CNY	-7.28%
2008 Q4	395.42 Million CNY	3.02%
2007 Q3	382.33 Million CNY	-2.81%
2007 Q4	403.22 Million CNY	5.46%
2007 FY	403.22 Million CNY	1.99%
2007 Q1	428.03 Million CNY	8.27%
2007 Q2	393.37 Million CNY	-8.1%
2006 Q4	395.34 Million CNY	24.19%
2006 Q3	318.34 Million CNY	-8.81%
2006 Q2	349.11 Million CNY	5.19%
2006 Q1	331.87 Million CNY	2.8%
2006 FY	395.34 Million CNY	22.46%
2005 FY	322.84 Million CNY	29.68%
2005 Q1	254.38 Million CNY	2.18%
2005 Q2	285.27 Million CNY	12.14%
2005 Q4	322.84 Million CNY	1.22%
2005 Q3	318.95 Million CNY	11.8%
2004 FY	248.95 Million CNY	-8.16%
2004 Q4	248.95 Million CNY	-6.18%
2004 Q3	265.34 Million CNY	1.23%
2004 Q2	262.12 Million CNY	-2.84%
2004 Q1	269.79 Million CNY	-0.47%
2003 Q1	225.5 Million CNY	7.59%
2003 Q2	218.02 Million CNY	-3.31%
2003 Q4	271.06 Million CNY	31.79%
2003 FY	271.06 Million CNY	29.33%
2003 Q3	205.67 Million CNY	-5.66%
2002 Q3	246.55 Million CNY	-27.81%
2002 Q1	340.03 Million CNY	-7.42%
2002 FY	209.59 Million CNY	-42.94%
2002 Q4	209.59 Million CNY	-14.99%
2002 Q2	341.52 Million CNY	0.44%
2001 Q2	252.89 Million CNY	0.0%
2001 Q4	367.3 Million CNY	0.0%
2001 FY	367.3 Million CNY	50.29%
2000 Q2	223.72 Million CNY	0.0%
2000 FY	244.4 Million CNY	-0.34%
2000 Q4	244.4 Million CNY	0.0%
1999 Q4	245.24 Million CNY	0.0%
1999 FY	245.24 Million CNY	-4.46%
1999 Q2	218.64 Million CNY	0.0%
1998 Q4	256.69 Million CNY	0.0%
1998 Q2	275.71 Million CNY	0.0%
1998 FY	256.69 Million CNY	-19.66%
1997 Q2	227.67 Million CNY	0.0%
1997 Q4	319.5 Million CNY	0.0%
1997 FY	319.5 Million CNY	76.5%
1996 Q4	181.02 Million CNY	0.0%
1996 FY	181.02 Million CNY	-3.57%
1996 Q2	199.41 Million CNY	0.0%
1995 Q4	187.72 Million CNY	0.0%
1995 Q2	112.54 Million CNY	0.0%
1995 FY	187.72 Million CNY	70.8%
1994 Q2	65.81 Million CNY	0.0%
1994 FY	109.9 Million CNY	145.09%
1993 Q2	44.34 Million CNY	0.0%
1993 Q4	44.84 Million CNY	0.0%
1993 FY	44.84 Million CNY	24.05%
1992 FY	36.15 Million CNY	0.0%

Peer Total Liabilities Comparison of Vcanbio Cell & Gene Engineering Corp., Ltd

Name	Total Liabilities	Total Liabilities Difference
Beijing Tiantan Biological Products Co., Ltd.	1.33 Billion CNY	-20.884%
JiangSu WuZhong Pharmaceutical Development Co., Ltd.	2.56 Billion CNY	37.025%
Jinyu Bio-technology Co., Ltd.	1.21 Billion CNY	-32.448%
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong	6.65 Billion CNY	75.751%
Zhejiang Ausun Pharmaceutical Co., Ltd.	809.99 Million CNY	-99.106%
DaShenLin Pharmaceutical Group Co., Ltd.	16.17 Billion CNY	90.027%
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	2.79 Billion CNY	42.355%
GuiZhou SanLi Pharmaceutical Co.,Ltd	1.17 Billion CNY	-37.24%
Pulike Biological Engineering, Inc.	538.33 Million CNY	-199.581%
Beijing Konruns Pharmaceutical Co.,Ltd.	418.43 Million CNY	-285.42%
Shanghai Hile Bio-Technology Co., Ltd.	482.95 Million CNY	-233.931%
Qingdao Vland Biotech INC.	1.15 Billion CNY	-39.843%
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.	1 Billion CNY	-60.781%
Aurisco Pharmaceutical Co.,Ltd.	607.02 Million CNY	-165.68%
Zhejiang East Asia Pharmaceutical Co., Ltd.	1.32 Billion CNY	-21.435%
Hainan Huluwa Pharmaceutical Group Co., Ltd.	1.9 Billion CNY	15.171%
Mabwell (Shanghai) Bioscience Co., Ltd.	1.88 Billion CNY	14.298%
Beijing Hotgen Biotech Co., Ltd.	202.56 Million CNY	-696.173%
Assure Tech (Hangzhou) Co., Ltd.	683.82 Million CNY	-135.841%
Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.	1.28 Billion CNY	-25.293%
Cabio Biotech (Wuhan) Co., Ltd.	117.6 Million CNY	-1271.364%
Shanghai Shen Lian Biomedical Corporation	86.92 Million CNY	-1755.3%
Nanjing Vazyme Biotech Co., Ltd.	1.69 Billion CNY	4.881%
Shandong Kexing Bioproducts Co,.Ltd	1.4 Billion CNY	-15.171%
Shanghai Junshi Biosciences Co., Ltd.	3.83 Billion CNY	57.988%
Shanghai Model Organisms Center, Inc.	260.98 Million CNY	-517.945%
Suzhou Zelgen Biopharmaceuticals Co., Ltd.	1.23 Billion CNY	-31.03%
Xiamen Amoytop Biotech Co., Ltd.	479.68 Million CNY	-236.208%
Novogene Co., Ltd.	1.12 Billion CNY	-43.92%
Shanghai ZJ Bio-Tech Co., Ltd.	241.66 Million CNY	-567.358%
Chengdu Olymvax Biopharmaceuticals Inc.	681.84 Million CNY	-136.528%
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd	308.14 Million CNY	-423.377%
Shanghai Haohai Biological Technology Co., Ltd.	1.07 Billion CNY	-50.081%
Jiangsu Bioperfectus Technologies Co., Ltd.	501.3 Million CNY	-221.706%
Jiangsu Aidea Pharmaceutical Co., Ltd.	621.02 Million CNY	-159.69%
Chengdu Easton Biopharmaceuticals Co., Ltd.	743.33 Million CNY	-116.961%
Sinocelltech Group Limited	3.21 Billion CNY	49.899%
Wuhan Keqian Biology Co.,Ltd	833.59 Million CNY	-93.469%
Shanghai Allist Pharmaceuticals Co., Ltd.	394.21 Million CNY	-309.1%
Anhui Huaheng Biotechnology Co., Ltd.	2.14 Billion CNY	24.799%
Youcare Pharmaceutical Group Co., Ltd.	2.31 Billion CNY	30.294%
Jiangsu gdk Biotechnology Co., Ltd.	260.51 Million CNY	-519.049%
Beijing Kawin Technology Share-Holding Co., Ltd.	663.01 Million CNY	-143.245%
Hangzhou Biotest Biotech Co.,Ltd.	158.82 Million CNY	-915.448%

Global Stocks Search

Vcanbio Cell & Gene Engineering Corp., Ltd (600645.SS)

Total Liabilities Summary of Vcanbio Cell & Gene Engineering Corp., Ltd

Annual Total Liabilities Chart of Vcanbio Cell & Gene Engineering Corp., Ltd (2023 - 1992)

Historical Annual Total Liabilities of Vcanbio Cell & Gene Engineering Corp., Ltd (2023 - 1992)

Peer Total Liabilities Comparison of Vcanbio Cell & Gene Engineering Corp., Ltd